Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Brian P. Danysh"'
Autor:
Jesus Paez-Mayorga, Andrew L. Chen, Sivareddy Kotla, Yunting Tao, Rei J. Abe, Emma D. He, Brian P. Danysh, Marie-Claude C. Hofmann, Nhat-Tu Le
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 5 (2018)
Ponatinib is a multi-targeted third generation tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukemia (CML) patients harboring the Abelson (Abl)-breakpoint cluster region (Bcr) T315I mutation. In spite of having superb clin
Externí odkaz:
https://doaj.org/article/b643074e36f24357bf3ad822cb1486cc
Publikováno v:
Theranostics, Vol 2, Iss 8, Pp 777-787 (2012)
MUC1 is a large, heavily glycosylated transmembrane glycoprotein that is proposed to create a protective microenvironment in many adenocarcinomas. Here we compare MUC1 and the well studied cell surface receptor target, EGFR, as gold nanoparticle (AuN
Externí odkaz:
https://doaj.org/article/f538be66c0e645b3b99253f7f945a82e
Autor:
Aishath Naeem, Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen Martindale, Yinglu Zhou, Yue Ren, Svitlana Tyekucheva, Annette S. Kim, Stacey M. Fernandes, Gordon Saksena, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P. Danysh, Kara Slowik, Raquel A. Jacobs, Matthew S. Davids, James A. Lederer, Rula Zain, C. I. Edvard Smith, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown
Publikováno v:
Blood Advances. 7:1929-1943
Covalent inhibitors of Bruton tyrosine kinase (BTK) have transformed the therapy of chronic lymphocytic leukemia (CLL), but continuous therapy has been complicated by the development of resistance. The most common resistance mechanism in patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8383f4c725051ef015310abdc3f2d39
https://doi.org/10.1182/bloodadvances.2022008447
https://doi.org/10.1182/bloodadvances.2022008447
Autor:
Erin M. Parry, Ignaty Leshchiner, Romain Guièze, Connor Johnson, Eugen Tausch, Sameer A. Parikh, Camilla Lemvigh, Julien Broséus, Sébastien Hergalant, Conor Messer, Filippo Utro, Chaya Levovitz, Kahn Rhrissorrakrai, Liang Li, Daniel Rosebrock, Shanye Yin, Stephanie Deng, Kara Slowik, Raquel Jacobs, Teddy Huang, Shuqiang Li, Geoff Fell, Robert Redd, Ziao Lin, Binyamin A. Knisbacher, Dimitri Livitz, Christof Schneider, Neil Ruthen, Liudmila Elagina, Amaro Taylor-Weiner, Bria Persaud, Aina Martinez, Stacey M. Fernandes, Noelia Purroy, Annabelle J. Anandappa, Jialin Ma, Julian Hess, Laura Z. Rassenti, Thomas J. Kipps, Nitin Jain, William Wierda, Florence Cymbalista, Pierre Feugier, Neil E. Kay, Kenneth J. Livak, Brian P. Danysh, Chip Stewart, Donna Neuberg, Matthew S. Davids, Jennifer R. Brown, Laxmi Parida, Stephan Stilgenbauer, Gad Getz, Catherine J. Wu
Publikováno v:
Nature Medicine
Nature Medicine, 2023, 29 (1), pp.158-169. ⟨10.1038/s41591-022-02113-6⟩
Nature Medicine, 2023, 29 (1), pp.158-169. ⟨10.1038/s41591-022-02113-6⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae467b24caea910b611486b7f4e015e
https://doi.org/10.1038/s41591-022-02113-6
https://doi.org/10.1038/s41591-022-02113-6
Autor:
Erin Michelle Parry, Romain Guieze, Ignaty Leshchiner, Connor Johnson, Eugen Tausch, Sameer A. Parikh, Camilla K Lemvigh, Julien Broséus, Sébastien Hergalant, Connor Messer, Filippo Utro, Chaya Levovitz, Kahn Rhrissorrakrai, Liang Li, Shuqiang Li, Geoffrey G Fell, Robert A. Redd, Ziao Lin, Binyamin A. Knisbacher, Christof Schneider, Stacey M. Fernandes, Julian M. Hess, Laura Z. Rassenti, Thomas J. Kipps, Nitin Jain, William G. Wierda, Florence Cymbalista, Pierre Feugier, Neil E. Kay, Kenneth J Livak, Brian P Danysh, Chip Stewart, Donna S. Neuberg, Matthew S. Davids, Jennifer R. Brown, Laxmi Parida, Stephan Stilgenbauer, Gad Getz, Catherine J. Wu
Publikováno v:
Blood. 140:1530-1533
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::428df9701ef7e6b22b9bd2cad252c8bc
https://doi.org/10.1182/blood-2022-160335
https://doi.org/10.1182/blood-2022-160335
Autor:
Jasneet Kaur Khalsa, Justin Cha, Filippo Utro, Aishath Naeem, Ishwarya Murali, Yanan Kuang, Kevin A. Vasquez, Liang Li, Svitlana Tyekucheva, Stacey M. Fernandes, Lauren Veronese, Romain Guieze, Binu Kandathilparambil Sasi, Zixu Wang, John-Hanson Machado, Harrison P. Bai, Maryam Alasfour, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P Danysh, Kara Slowik, Raquel A. Jacobs, Matthew S. Davids, Cloud P. Paweletz, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown
Publikováno v:
Blood Journal.
Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a382fac79b98504ad575401318eced3
https://doi.org/10.1182/blood.2022016600
https://doi.org/10.1182/blood.2022016600
Autor:
Yosef Yarden, Eytan Ruppin, Gad Getz, Aviv Regev, Joan S. Brugge, Rami I. Aqeilan, Trever G. Bivona, Laxmi Parida, Stefan Wiemann, Jideofor Ezike, Collin M. Blakely, Moshe Oren, Andrea Ardizzoni, Michelangelo Fiorentino, Mattia Lauriola, Brian P. Danysh, Diana Drago-Garcia, Youngmin Chung, Suvendu Giri, Arunachalam Sekar, Wei Wu, D. Lucas Kerr, Alexander Brandis, Sanju Sinha, Welles Robinson, Simone Borgoni, Rishita Chatterjee, Aakanksha Verma, Arturo Simoni-Nieves, Soma Ghosh, Rainer Will, Saptaparna Mukherjee, Moshit Lindzen, Sara Oster, Yaara Oren, Benny Zhitomirsky, Joo Sang Lee, Nishanth Belugali Nataraj, Ashish Noronha
Anticancer therapies have been limited by the emergence of mutations and other adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone factors that allow for continuous replication at the cost of mutagenesis. We i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a90156dccca93cef0832f1138ce45eef
https://doi.org/10.1158/2159-8290.c.6549711
https://doi.org/10.1158/2159-8290.c.6549711
Autor:
Yosef Yarden, Eytan Ruppin, Gad Getz, Aviv Regev, Joan S. Brugge, Rami I. Aqeilan, Trever G. Bivona, Laxmi Parida, Stefan Wiemann, Jideofor Ezike, Collin M. Blakely, Moshe Oren, Andrea Ardizzoni, Michelangelo Fiorentino, Mattia Lauriola, Brian P. Danysh, Diana Drago-Garcia, Youngmin Chung, Suvendu Giri, Arunachalam Sekar, Wei Wu, D. Lucas Kerr, Alexander Brandis, Sanju Sinha, Welles Robinson, Simone Borgoni, Rishita Chatterjee, Aakanksha Verma, Arturo Simoni-Nieves, Soma Ghosh, Rainer Will, Saptaparna Mukherjee, Moshit Lindzen, Sara Oster, Yaara Oren, Benny Zhitomirsky, Joo Sang Lee, Nishanth Belugali Nataraj, Ashish Noronha
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5b3d798497aa0ca157a505f562f91a6
https://doi.org/10.1158/2159-8290.22541643.v1
https://doi.org/10.1158/2159-8290.22541643.v1
Autor:
Yosef Yarden, Eytan Ruppin, Gad Getz, Aviv Regev, Joan S. Brugge, Rami I. Aqeilan, Trever G. Bivona, Laxmi Parida, Stefan Wiemann, Jideofor Ezike, Collin M. Blakely, Moshe Oren, Andrea Ardizzoni, Michelangelo Fiorentino, Mattia Lauriola, Brian P. Danysh, Diana Drago-Garcia, Youngmin Chung, Suvendu Giri, Arunachalam Sekar, Wei Wu, D. Lucas Kerr, Alexander Brandis, Sanju Sinha, Welles Robinson, Simone Borgoni, Rishita Chatterjee, Aakanksha Verma, Arturo Simoni-Nieves, Soma Ghosh, Rainer Will, Saptaparna Mukherjee, Moshit Lindzen, Sara Oster, Yaara Oren, Benny Zhitomirsky, Joo Sang Lee, Nishanth Belugali Nataraj, Ashish Noronha
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14e7bdbe0faeb9783a3dfad67e1dd091
https://doi.org/10.1158/2159-8290.22541646.v1
https://doi.org/10.1158/2159-8290.22541646.v1
Autor:
Leif W. Ellisen, Aditya Bardia, Gad Getz, Dejan Juric, Laxmi Parida, Steven J. Isakoff, James R. Stone, Avinash Kambadakone, Charlotte S. Walmsley, Elyssa Denault, Chaya Levovitz, Filippo Utro, Kahn Rhrissorrakrai, Raquel A. Jacobs, Kara Slowik, Brian P. Danysh, Daniel McLoughlin, Elizabeth E. Martin, Nayana Thimmiah, Ignaty Leshchiner, Sheng Sun, James T. Coates
Sacituzumab govitecan (SG), the first antibody–drug conjugate (ADC) approved for triple-negative breast cancer, incorporates the anti-TROP2 antibody hRS7 conjugated to a topoisomerase-1 (TOP1) inhibitor payload. We sought to identify mechanisms of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e216b65b6323310fb4109676f0f444f4
https://doi.org/10.1158/2159-8290.c.6549032.v1
https://doi.org/10.1158/2159-8290.c.6549032.v1